UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Burdensome Research Procedures in Trials: Why Less Is More

JNCI : Journal of the National Cancer Institute, 2017-04, Vol.109 (4)

2017

Volltextzugriff (PDF)

Measuring financial toxicity as a clinically relevant patient‐reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST)

Cancer, 2017-02, Vol.123 (3), p.476-484

2017

Volltextzugriff (PDF)

The development of a financial toxicity patient‐reported outcome in cancer: The COST measure

Cancer, 2014-10, Vol.120 (20), p.3245-3253

2014

Volltextzugriff (PDF)

US Government Payer-Funded Trials to Address Oncology's Drug-Dosing Conundrum: A Congressional Call to Action?

Journal of clinical oncology, 2023-05, Vol.41 (14), p.2488-2492

2023

Volltextzugriff (PDF)

Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message?

Journal of clinical oncology, 2021-11, Vol.39 (31), p.3423-3426

2021

Volltextzugriff (PDF)

Lurbinectedin-induced thrombocytopenia: the role of body surface area

Cancer chemotherapy and pharmacology, 2022-05, Vol.89 (5), p.573-575

2022

Volltextzugriff (PDF)

Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine

Nature reviews. Drug discovery, 2017-01, Vol.16 (1), p.1-70

2017

Volltextzugriff (PDF)

Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue

PLoS genetics, 2011-05, Vol.7 (5), p.e1002078

2011

Volltextzugriff (PDF)

Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies

British journal of cancer, 2023-10, Vol.129 (9), p.1389-1396

2023

Volltextzugriff (PDF)

Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer

Journal of clinical oncology, 2011-07, Vol.29 (19), p.2660-2666

2011

Volltextzugriff (PDF)

Optimizing the doses of cancer drugs after usual dose finding

Clinical trials (London, England), 2024-06, Vol.21 (3), p.340-349

2024

Volltextzugriff (PDF)

Ethical Framework for Including Research Biopsies in Oncology Clinical Trials: American Society of Clinical Oncology Research Statement

Journal of clinical oncology, 2019-09, Vol.37 (26), p.2368-2377

2019

Volltextzugriff (PDF)

Negative innovation: when patents are bad for patients

Nature biotechnology, 2021-08, Vol.39 (8), p.914-916

2021

Volltextzugriff (PDF)

Therapeutic Drug Monitoring of Oral Oncology Drugs: Another Example of Maslow's Hammer

Clinical pharmacology and therapeutics, 2024-09, Vol.116 (3), p.508-510

Ratain, Mark J.

2024

Volltextzugriff (PDF)

A Genome-Wide Association Study Identifies Novel Loci for Paclitaxel-Induced Sensory Peripheral Neuropathy in CALGB 40101

Clinical cancer research, 2012-09, Vol.18 (18), p.5099-5109

2012

Volltextzugriff (PDF)

Interventional Pharmacoeconomics—A New Discipline for a Cost-Constrained Environment

JAMA oncology, 2019-08, Vol.5 (8), p.1097

2019

Volltextzugriff (PDF)

Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and Pharmacokinetics

Journal of clinical oncology, 2009-06, Vol.27 (16), p.2604-2614

2009

Volltextzugriff (PDF)

Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19

JAMA oncology, 2020-11, Vol.6 (11), p.1694

2020

Volltextzugriff (PDF)

Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Journal of clinical oncology, 2006-06, Vol.24 (16), p.2505-2512

2006

Volltextzugriff (PDF)

Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients

British journal of cancer, 2022-02, Vol.126 (2), p.265-274

2022

Volltextzugriff (PDF)

Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents

Clinical cancer research, 2010-03, Vol.16 (6), p.1745-1755

2010

Volltextzugriff (PDF)

Genetic Variants in the UDP-glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of Irinotecan

Journal of clinical oncology, 2004-04, Vol.22 (8), p.1382-1388

2004

Volltextzugriff (PDF)

Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacodynamic Biomarker Study of Sorafenib in Metastatic Renal Carcinoma

Journal of clinical oncology, 2008-10, Vol.26 (28), p.4572-4578

2008

Volltextzugriff (PDF)

Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases

Drug metabolism and disposition, 2010-01, Vol.38 (1), p.32-39

2010

Volltextzugriff (PDF)

Common variation in a long non-coding RNA gene modulates variation of circulating TGF-β2 levels in metastatic colorectal cancer patients (Alliance)

BMC genomics, 2024-05, Vol.25 (1), p.473-10, Article 473

2024

Volltextzugriff (PDF)

1 – 25 von 626

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(608)
Mit Volltextzugriff
(532)

Publikationsform

Artikel
(618)
Buchkapitel
(3)
Texte
(3)
Berichte
(1)
Reviews
(1)

Sprache

Englisch
(626)

Erscheinungsjahr

n.n

Thema

Science & Technology
(449)
Life Sciences & Biomedicine
(442)
Humans
(428)
Oncology
(311)
Biological And Medical Sciences
(218)
Medical Sciences
(215)
Female
(198)
Male
(188)
Pharmacology. Drug Treatments
(180)
Middle Aged
(172)
Aged
(163)
Adult
(147)
Antineoplastic Agents
(140)
Pharmacology & Pharmacy
(140)
Neoplasms - Drug Therapy
(131)
Chemotherapy
(90)
Tumors
(68)
Aged, 80 And Over
(67)
Antineoplastic Agents - Therapeutic Use
(57)
Dose-Response Relationship, Drug
(56)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(436)
EZB Electronic Journals Library
(405)
Publisher or Other Site
(357)
Journals@Ovid Full Text
(348)
IngentaConnect Journals
(224)
IngentaConnect Journals
(129)
Wiley-Blackwell Full Collection
(100)
SpringerLink
(62)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(53)
Wiley Online Library
(48)
Oxford Journals
(36)
Oxford Journals 2020 Medicine
(34)
Nature
(34)
Nexis Uni
(27)
Elsevier ScienceDirect Journals Complete
(26)
HEAL-Link subscriptions: Springer Book Series
(23)
EZB-NALI5-00465 Elsevier Archive NL
(17)
Taylor & Francis
(14)
Access via Taylor & Francis
(12)
Taylor & Francis Online
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Burdensome Research Procedures in Trials: Why Less Is More

Measuring financial toxicity as a clinically relevant patient‐reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST)

The development of a financial toxicity patient‐reported outcome in cancer: The COST measure

US Government Payer-Funded Trials to Address Oncology's Drug-Dosing Conundrum: A Congressional Call to Action?

Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message?

Lurbinectedin-induced thrombocytopenia: the role of body surface area

Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine

Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue

Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies

Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer

Optimizing the doses of cancer drugs after usual dose finding

Ethical Framework for Including Research Biopsies in Oncology Clinical Trials: American Society of Clinical Oncology Research Statement

Negative innovation: when patents are bad for patients

Therapeutic Drug Monitoring of Oral Oncology Drugs: Another Example of Maslow's Hammer

A Genome-Wide Association Study Identifies Novel Loci for Paclitaxel-Induced Sensory Peripheral Neuropathy in CALGB 40101

Interventional Pharmacoeconomics—A New Discipline for a Cost-Constrained Environment

Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and Pharmacokinetics

Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19

Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients

Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents

Genetic Variants in the UDP-glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of Irinotecan

Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacodynamic Biomarker Study of Sorafenib in Metastatic Renal Carcinoma

Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases

Common variation in a long non-coding RNA gene modulates variation of circulating TGF-β2 levels in metastatic colorectal cancer patients (Alliance)

Suchergebnisse filtern